Cognition Therapeutics (CGTX): Price and Financial Metrics
CGTX Price/Volume Stats
| Current price | $0.29 | 52-week high | $2.54 |
| Prev. close | $0.31 | 52-week low | $0.22 |
| Day low | $0.27 | Volume | 7,063,200 |
| Day high | $0.30 | Avg. volume | 1,445,175 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $0.51 | Market Cap | 17.98M |
CGTX Stock Price Chart Interactive Chart >
Cognition Therapeutics (CGTX) Company Bio
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
CGTX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CGTX Price Returns
| 1-mo | -18.24% |
| 3-mo | -32.34% |
| 6-mo | -31.59% |
| 1-year | -84.15% |
| 3-year | -87.45% |
| 5-year | N/A |
| YTD | -58.65% |
| 2024 | -62.09% |
| 2023 | -11.90% |
| 2022 | -66.77% |
| 2021 | N/A |
| 2020 | N/A |